GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PPD Inc (NAS:PPD) » Definitions » Cash Conversion Cycle

PPD (PPD) Cash Conversion Cycle : 42.59 (As of Sep. 2021)


View and export this data going back to 2020. Start your Free Trial

What is PPD Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

PPD's Days Sales Outstanding for the three months ended in Sep. 2021 was 60.22.
PPD's Days Inventory for the three months ended in Sep. 2021 was 0.
PPD's Days Payable for the three months ended in Sep. 2021 was 17.63.
Therefore, PPD's Cash Conversion Cycle (CCC) for the three months ended in Sep. 2021 was 42.59.


PPD Cash Conversion Cycle Historical Data

The historical data trend for PPD's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PPD Cash Conversion Cycle Chart

PPD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
Cash Conversion Cycle
- 48.39 47.75 47.98 37.58

PPD Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.28 35.19 35.93 39.85 42.59

Competitive Comparison of PPD's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, PPD's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PPD's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PPD's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where PPD's Cash Conversion Cycle falls into.



PPD Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

PPD's Cash Conversion Cycle for the fiscal year that ended in Dec. 2020 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=56.98+0-19.4
=37.58

PPD's Cash Conversion Cycle for the quarter that ended in Sep. 2021 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=60.22+0-17.63
=42.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PPD  (NAS:PPD) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


PPD Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of PPD's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


PPD (PPD) Business Description

Traded in Other Exchanges
N/A
Address
929 North Front Street, Wilmington, NC, USA, 28401
PPD is a global contract research organization that provides clinical trial and laboratory services to pharmaceutical, device, and diagnostic firms. The clinical development services segment offers outsourced trial services, spanning early- and late-stage trials, as well as peri- and post-approval trials, and the laboratory services segment includes both advanced lab testing and central lab services. The company was taken private in 2011 and went public again in 2020.. Thermo Fisher Scientific announced it will acquire PPD for $17.4 billion, which is scheduled to close by the end of 2021.
Executives
H&f Corporate Investors Viii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
H&f Corporate Investors Vii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
David Michael Johnston officer: See Remarks C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
David S Simmons director, officer: Chief Executive Officer PFIZER INC. ATTN. CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Glen Donovan officer: Chief Accounting Officer C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
Ronald E Garrow officer: See Remarks 2000 PURCHASE STREET, PURCHASE NY 10577
Karen Kaucic officer: See Remarks C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
Judd Hartman officer: See Remarks 3124 DEVER COURT WILMINGTON NC 28411
Jill Pellegrino officer: SVP & General Manager of AES C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
H&f Executives Vii, L.p. 10 percent owner ONE MARITIME PLAZA 12TH FLOOR SAN FRANCISCO CA 94111
Hellman & Friedman Investors Viii, L.p. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
P. Hunter Philbrick director C/O HELLMAN & FRIEDMAN INVESTORS, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Carlyle Partners Vi Holdings Ii, L.p. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Tc Group Vi, L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA ANVENE, N.W., WASHINGTON DC 20004
Tc Group Vi, L.p. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004